Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
28,156 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Lifestyle, anthropometric factors and clinically significant prostate cancer diagnosis in men with suspected prostate cancer.
Heiskanen E, Kalinen S, Chu RJ, Högerman M, Lamminen T, Taimen P, Jambor I, Aronen H, Merisaari H, Sainio T, Hakanen A, Ettala O, Laitinen K, Vasankari T, Kallonen T, Boström PJ, Promic study group. · Scand J Urol · 2026 · cited 0 timesclinical trial
- Ablative radiotherapy in castration-resistant prostate cancer.
Hölscher T, Lohaus F, Koi L, Kotzerke J, Hoberück S, Thomas C, Borkowetz A, Löck S, Krause M, Troost EGC. · BJU Int · 2026 · cited 1 timesOpen accessclinical trial, phase ii, randomized controlled trial
- Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer: A Randomized Clinical Trial.
Leong DP, Higano C, Cano Garcia C, Fradet V, Siemens DR, Niazi T, Shayegan B, Guha A, Cirne F, Selvanayagam JB, Violette PD, Valle FH, Lavallée LT, Duceppe E, Anderson P, Xavier D, Lopez-Lopez JP, Villareal Trujillo N, Galapo Kann A, Piccoli RK, Mourtzakis M, Sarid D, Narasimha S, Luke PPW, Hajjar LA, Lukka H, Klotz L, Balasubramanian K, Mian R, Agapay S, Rangarajan S, Karampatos S, Ng KKH, Avezum A, Devereaux PJ, Pinthus JH, RADICAL PC Investigators. · JAMA Intern Med · 2026 · cited 0 timesOpen accessmulticenter study, randomized controlled trial
- Digital supportive care in prostate cancer: a systematic review.
Paterson C, Coro D, Morris JN, Turner MR, Perrotta N, Godfrey M, Robertson A, Christina J. · Support Care Cancer · 2026 · cited 0 timesOpen accesssystematic review
- Prevalence of osteoporosis and low bone mass in men with prostate cancer: a systematic review and meta-analysis.
Ebrahimi M, Mohammadi A, Sarmadi S, Rahimnia R, Zare-Kaseb A, Reis LO, Shabestari AN, Sanaie N, Keshtkar A, Aghamir SMK. · Support Care Cancer · 2026 · cited 0 timesmeta-analysis, systematic review
- Stereotactic Prostate Cancer Ablative Re-Irradiation: A Systematic Review and Meta-Analysis (SPARE).
Gouveia AG, Tao J, Pond G, Dong K, Ye A, Rosa AA, Palhares DM, Villafuerte CJQ, Anselmo P, Moraes FY, Arcidiacono F, Olson R, Tsakiridis T. · Prostate · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- The Association Between Human Papillomavirus and Prostate Cancer: A Systematic Review and Meta-Analysis.
Botting-Provost S, Ng K, Laurie C, Noorani R, El-Zein M, Franco EL. · Int J Cancer · 2026 · cited 1 timesOpen accessmeta-analysis, systematic review
- Association of EBV infection with increased cancer aggressiveness in prostate cancer patients: A systematic review and meta-analysis.
Abidi SH, Fabiyi OT, Omarova Z, Sheikh A, Ahmed K, Bajpai R. · Adv Clin Exp Med · 2026 · cited 1 timesmeta-analysis, systematic review
- ADT Combinations With Radiation for Prostate Cancer: A Systematic Review and Meta-analysis.
Takayesu JSK, Xie T, Aldous J, Nasser B, Alumkal JJ, Dess RT, Reichert ZR, Schipper MJ, Spratt D, Suresh K, Jackson WC. · Int J Radiat Oncol Biol Phys · 2026 · cited 0 timesmeta-analysis, systematic review
- Investigation of a Prostate Cancer Radiation Response Signature in the Breast Cancer SweBCG91RT Randomized Trial.
Zhao SG, Holmberg E, Lundstedt D, Killander F, Niméus E, Sharifi MN, Sjöström M, Karlsson P. · Clin Cancer Res · 2026 · cited 0 timesrandomized controlled trial
- MRI-derived radiomics for prostate cancer active surveillance: a systematic review.
Kyle ET, Sweeney KJ, McCabe DH, O'Sullivan NJ, Corr A, Sheehy N, Meaney J, Lonergan P, McLoughlin LC, Kelly ME. · Eur J Radiol · 2026 · cited 0 timessystematic review
- Black Race Predicts Poor Compliance and Higher Prostate Cancer Risk in a Multinational Repeat Biopsy Cohort: Secondary Analysis From the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Clinical Trial.
Freedland AR, Moriera DM, Gong J, Freedland SJ. · Prostate · 2026 · cited 0 timesclinical trial, phase iii, multicenter study
- Active surveillance for intermediate-risk prostate cancer: a systematic review and pooled analysis.
Uleri A, Cella L, Long-Depaquit T, Sordelli F, Farré A, Caballero V, Comet J, Rajwa P, Diamand R, Tombal B, Roupret M, Kasivisvanathan V, Leapman MS, Ploussard G, Baboudjian M. · BJU Int · 2026 · cited 0 timesmeta-analysis, systematic review
- Integrating NCCN and LATITUDE in metastatic castration-sensitive prostate cancer: a TITAN analysis.
Hori T, Iwamoto H, Inaba T, Nakagawa R, Kamijima T, Makino T, Naito R, Kadomoto S, Yaegashi H, Shigehara K, Nohara T, Izumi K, Mizokami A. · World J Urol · 2026 · cited 0 timesclinical trial, phase iii, multicenter study
- From etiology to precision oncology: a systematic review of the causes and evolving treatments of prostate cancer.
Kisakye NI, Ayebazibwe G, Mary Amito P, Ajambo PD, Tirwomwe M, Tiko A, Pliers T, Owamukamaeli A, Nduhukire T, Chrispuss N, Mandera I, Owomugisha R, Terkimbi SD. · Front Oncol · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Mediterranean diet and risk of prostate cancer: a systematic review and meta-analysis of observational studies.
Jahnke TT, Holschuh C, Schlattmann P. · BMC Nutr · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Impact of leuprolide and goserelin on androgen suppression and adverse events in patients with prostate cancer.
Freitas CSM, Rocha-Silva F, Marques-Silva TA, de Oliveira ACR, da Silva SG, Santos Cardoso FD, Soares AN. · Can J Urol · 2026 · cited 0 timesrandomized controlled trial
- Prognostic value of ctDNA in patients with prostate cancer: a meta-analysis and trial sequential analysis.
Hao X, Xiao H, Li M, Wu J, Niu S, Xiong T, Wang P, Liu X. · BMC Cancer · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Prostate-specific antigen (PSA) test for prostate cancer screening.
Franco JV, Hwang EC, Jung JH, Vaimberg O, Ilic D, Cleves A, Dahm P. · Cochrane Database Syst Rev · 2026 · cited 5 timesmeta-analysis, systematic review
- The impact of prehabilitation on postoperative outcomes in patients undergoing radical prostatectomy for prostate cancer: a systematic review and meta-analysis.
Wan W, Shen L, Chang Y, Jin X. · Support Care Cancer · 2026 · cited 0 timesmeta-analysis, systematic review
- Perioperative Apalutamide in High-Risk Localized Prostate Cancer.
Taplin ME, Gleave M, Shore ND, Lopez-Gitlitz A, Kretschmer A, Efstathiou E, Nguyen PL, Damião R, Kamoto T, Ross A, Briganti A, Hadaschik BA, Heidenreich A, Juárez Soto Á, Ye H, Gotto G, Rooney B, Tian SK, Wetherhold L, Miladinovic B, McCarthy SA, Evans CP, Kibel AS, PROTEUS Investigators. · N Engl J Med · 2026 · cited 21 timesclinical trial, phase iii, multicenter study
- Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer.
Munzur AD, Herberts C, Kwan EM, Emmett L, Sandhu S, Buteau JP, Iravani A, Joshua AM, Francis RJ, Lee ST, Scott AM, Martin AJ, Stockler MR, Zhang AY, Williams SG, Bernales CQ, Donnellan G, Koudjanian M, Parekh K, Bacon JVW, Karsan A, Azad AA, Davis ID, Hofman MS, Wyatt AW. · Clin Cancer Res · 2026 · cited 8 timesclinical trial, phase ii, randomized controlled trial
- Prostate-specific antigen-based screening for prostate cancer: A systematic review to inform an American Cancer Society guideline.
Griffin JC, Shiau RL, Troutman CAB, Welsh A, Edwards E, Ajayi IA, Relevo R, Kondo KK. · Cancer · 2026 · cited 2 timesOpen accesssystematic review, review-article
- Development and pilot testing of a prostate cancer polygenic risk report.
Griffin JN, Danowski ME, Gerety HL, Lafferty K, Clayman ML, Antwi AA, Bertero MG, Brunette CA, Gillespie C, Guentert L, Lennon NJ, Martin J, Patel LS, Vassy JL. · BMC Med Genomics · 2026 · cited 0 timesOpen accessresearch support, u.s. gov't, p.h.s., randomized controlled trial
- Association of androgen deprivation therapy and acute kidney injury in patients with prostate cancer: a systematic review and meta-analysis of 72,980 patients.
Pires IZ, Fujimura AY, da Silva Gobbo MO, Sudo RYU, Milbradt TL, Filho NM, Carvalhal GF. · Cancer Chemother Pharmacol · 2026 · cited 0 timesmeta-analysis, systematic review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.